Cell and gene therapies in the EU are transforming treatment options for oncology, rare diseases, regenerative medicine, and inherited disorders.
To launch advanced therapy products in the EU, companies must follow the EU regulatory framework, where these products are defined as ATMPs under Regulation (EC) No. 1394/2007 and can be classified through EMA’s Committee for Advanced Therapies (CAT). Understanding the EU regulatory framework, from classification to commercialization, is crucial for regulatory teams.
Delays often occur not because science is weak but because of an incomplete strategy. This blog explains the EU regulatory pathway and what manufacturers need to prepare.
Background of Cell & Gene Therapy in EU
In the EU, these treatments are regulated under EU legislation as ATMPs, with oversight coordinated by EMA, which has been supported by orphan drug incentives, a centralized approval process, and research infrastructure. Cell and gene therapies are advanced biological treatments used to address complex and previously untreatable diseases, to cure diseases like autoimmune disorders, solid tumors, degenerative diseases, and genetic disorders.
Gene therapy prevents or treats disease by modifying genetic material by removing and altering genetic material.
Cell therapy uses viable cells to restore, replace, or modify biological function to combat illness by restoring function.
Compared with traditional pharmaceuticals, ATMP therapies require extra regulatory concerns. Instead of using the standard approval route, manufacturers must adhere to specific EU Regulatory Pathways for ATMPs.
What are Advanced Therapy Medicinal Products (ATMPs)?
In the European Union, the ATMPs include gene therapies, somatic cell therapies, tissue-engineered products, and combined ATMPs.
ATMPs are defined under Regulation (EC) No.1394/2007 [1] and are divided into four groups:
1. Gene Therapy Medicinal Products (GTMPs)
GTMPs contain recombinant nucleic acid used to regulate, repair, delete, add, or replace a genetic sequence.
Examples- CAR-T products with a genetic modification component, Gene-editing products, gene replacement therapy, and Viral vector-based treatments.
2. Tissue Engineered Products (TEPs)
TEPs are used in the case of regenerative, repair, or replacement of human tissue.
Examples- Engineered cartilage, Bioengineered tissue scaffolds, and Skin substitutes.
3. Somatic Cell Therapy Medicinal Products (sCTMPs)
Somatic Cell Therapy Medicinal Products (sCTMPs) are based on cells that have been substantially manipulated or used for a different essential function in the recipient than in the donor.
Examples- Immune Cell therapies, expanded stem cell products, and modified dendritic cell therapies
4. Combined ATMPs
Combined ATMPs contain both a biological component and a medical device.
Examples- Cells embedded in a scaffold or matrix, Implantable regenerative constructs.
Key Insight: Understanding the correct product classification is a critical early regulatory step. Misclassification can lead to delays, application rejection, or additional studies.
EMA’s Regulatory Pathway for ATMPs
All ATMPs are approved through the EU centralized authorization procedure coordinated by EMA. After approval, the product can launch in the market across the EU.
Step 1: ATMP Classification
Manufacturers should request an official ATMP classification from EMA’s Committee for Advanced Therapies early in development.
During the classification confirmation process, the classification procedure evaluates:
- Whether the product qualifies as an ATMP
- Which ATMP category applies
- Whether additional device or GMO requirements are relevant.
Step 2: Engage EMA with Scientific Advice
Manufacturers are encouraged to seek scientific advice from the EMA during early development.
Scientific advice may address:
- Manufacturing strategy
- Non-clinical study design
- Clinical endpoints
- Comparability plans
- Long-term safety follow-up
- Potency assays
Step 3: Clinical Trial Application (CTA)
Regulators frequently examine their ATMPs’ complex processes, such as batch consistency, starting material control, manufacturing methodology, patient follow-up duration, and product characterization.
CTA is submitted via the Clinical Trials Information System (CTIS) under Regulation (EU) No. 536/2014.
For ATMPs, the CTA usually includes:
- Quality and Manufacturing data
- Viral safety information
- Biodistribution studies
- Shedding assessments
- Clinical trial protocol
- Environmental risk assessment
Step 4: GMP standards in Manufacturing
When production takes place across multiple or hospital-based settings, companies need to show that every manufacturing site can produce the same product quality.
Manufacturers must follow EU Good Manufacturing Practice (GMP), including specific requirements for:
- Aseptic processing
- Viral vector production
- Cell sourcing and donor eligibility
- Chain of identity and chain of custody
- Stability and storage conditions
Step 5: Submission of the Marketing Authorization Application (MAA)
All ATMPs must go through the EMA centralized approval route. The Marketing Authorization Application is submitted to the EMA and evaluated by CAT (scientific assessment), CHMP (final opinion), and approved by the European Commission.
The assessment generally follows this sequence:
- CAT reviews quality, safety, and efficacy data.
- CAT prepares a draft opinion
- CHMP adopts the final scientific opinion
- The European Commission grants final marketing authorization.
Under the centralized procedure, the standard EMA timeline for review is approximately ~210 active days, excluding clock stops.
Step 6: Post-Approval Obligation
ATMP manufacturers remain subject to extensive post-authorization responsibilities. These commonly include:
- Long-term safety monitoring
- Risk Management Plans (RMPs)
- Product traceability requirements, which may extend up to 30 years depending on the product
- Pharmacovigilance reporting
- Patient registration
Long-term follow-up for gene therapies may extend for 5 to 15 years, according to the risk profile.
Common Challenges Affecting ATMP Manufacturers
Despite scientific progress, bringing ATMPs to market remains a challenge for many companies because of repeated regulatory and practical challenges.
Variations in Production: Differences between patients or donors can impact comparability, and scale-up production without changing product features.
Regulatory classification gaps: Wrong classification between ATMPs, medicinal products, transplant, and medical devices, which can lead to delays.
Unclear Product Profile: Lack of a product profile, including the mechanism of action, potency, and purity. It can create a challenge during development.
Biosafety and Environmental Risk: In these therapies, viral vectors and genetically modified cells are involved, which require biosafety assessments, shedding studies, and GMO approval.
Clinical Trial: Population limitation in rare diseases, comparison groups are absent, and dependence on surrogate endpoints.
Regulatory Compliance Tips
For enhancing the probability of successful approval, manufacturers should adhere to well-structured compliance.
Early Regulatory Engagement: Classification and scientific advice can prevent costly redesign later. Do not wait until the clinical phase to interact with the EMA.
CMC Focused Process: Ensure that the dossier clearly explains detailed chemistry, manufacturing, and control documentation.
Post-approval safety monitoring: Manufacturers must maintain a monitoring system, patients’ records, follow-up cases, and pharmacovigilance.
Align with Clinical and Manufacturing Development: Teamwork between clinical and CMC can prevent comparability issues.
Regulatory Guidance: Consult with external regulatory experts, who can help optimize strategy and ease EMA interaction.
Conclusion
Cell and gene therapy represents a rapidly advancing and high-impact segment of the biopharmaceutical industry in the EU, but the regulatory route remains demanding. The EMA’s ATMPs approach is designed to support therapeutic innovation and ensure the safety and efficacy of these complex therapies.
Manufacturers that achieve success focus on early regulatory plans, proactive EMA engagement, establish a strong CMC strategy, and prepare for long-term responsibilities before submission.
ATMP approval requires coordination across classification, manufacturing, clinical development, and post-authorization planning.
Our regulatory affairs services support through every stage of the ATMP lifecycle, including:
- ATMP classification strategy
- Clinical Trial Application support
- Post-approval and Pharmacovigilance compliance
- GMP and CMC documentation